Martingale Asset Management L P Has $1.87 Million Holdings in Supernus Pharmaceuticals, Inc. $SUPN

Key Points

• Martingale Asset Management L P has increased its stake in Supernus Pharmaceuticals by 28.3%, now owning 57,199 shares valued at approximately $1.87 million.
• Wall Street analysts have shown confidence in Supernus Pharmaceuticals, with Zacks Research upgrading its rating to "hold" and Cantor Fitzgerald raising the target price from $42.00 to $46.00.
• Despite some insider selling, Supernus Pharmaceuticals' stock rose by 3.6%, reaching a recent price of $44.88 with a market cap of $2.52 billion.

Martingale Asset Management L P increased its position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 28.3% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 57,199 shares of the specialty pharmaceutical company's stock after purchasing an additional 12,607 shares during the quarter. Martingale Asset Management L P owned approximately 0.10% of Supernus Pharmaceuticals worth $1,873,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. Raiffeisen Bank International AG acquired a new stake in Supernus Pharmaceuticals during the fourth quarter valued at approximately $25,000. Financial Management Professionals Inc. bought a new position in Supernus Pharmaceuticals during the 1st quarter valued at about $30,000. Versant Capital Management Inc boosted its position in Supernus Pharmaceuticals by 6,931.3% in the first quarter. Versant Capital Management Inc now owns 1,125 shares of the specialty pharmaceutical company's stock valued at $37,000 after buying an additional 1,109 shares in the last quarter. Caitong International Asset Management Co. Ltd bought a new stake in Supernus Pharmaceuticals during the 1st quarter worth approximately $41,000. Finally, GF Fund Management CO. LTD. acquired a new stake in Supernus Pharmaceuticals during the 4th quarter valued at $42,000.

Insider Buying and Selling

In other Supernus Pharmaceuticals news, CEO Jack A. Khattar sold 140,000 shares of the business's stock in a transaction dated Wednesday, August 6th. The stock was sold at an average price of $42.02, for a total value of $5,882,800.00. Following the completion of the transaction, the chief executive officer directly owned 1,030,183 shares of the company's stock, valued at approximately $43,288,289.66. The trade was a 11.96% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Bethany Sensenig sold 5,369 shares of the firm's stock in a transaction dated Thursday, August 14th. The stock was sold at an average price of $42.25, for a total value of $226,840.25. The disclosure for this sale can be found here. Insiders have sold a total of 164,606 shares of company stock valued at $6,948,865 over the last 90 days. 8.80% of the stock is owned by corporate insiders.

Supernus Pharmaceuticals Stock Up 1.7%

NASDAQ SUPN traded up $0.75 on Wednesday, reaching $45.07. The company had a trading volume of 655,460 shares, compared to its average volume of 639,966. Supernus Pharmaceuticals, Inc. has a 52 week low of $29.16 and a 52 week high of $45.60. The stock's 50 day moving average is $35.88 and its 200-day moving average is $33.77. The stock has a market cap of $2.53 billion, a price-to-earnings ratio of 39.19 and a beta of 0.74.

Analysts Set New Price Targets

Several research analysts recently issued reports on SUPN shares. Cantor Fitzgerald upped their price target on shares of Supernus Pharmaceuticals from $42.00 to $46.00 and gave the stock an "overweight" rating in a research report on Wednesday, August 6th. Wall Street Zen upgraded shares of Supernus Pharmaceuticals from a "hold" rating to a "buy" rating in a research report on Saturday, August 2nd. Finally, Zacks Research raised Supernus Pharmaceuticals from a "strong sell" rating to a "hold" rating in a research note on Tuesday, August 19th. Two equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $41.00.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.